Effortless Comfort: Smartmi Evaporative Humidifier 3Lite Offers Mist-Free, Filter-Free, Smart Humidification
BEIJING, Nov. 11, 2024 /PRNewswire/ -- Smartmi, a global pioneer of home appliance consumption upgrade, today is thrilled to announce the launch of the Smartmi Evaporative Humidifier 3lite. This innovative humidifier is designed to enhance everyday living with its slogan, "Smart Humidification, Simple Living." Featuring mist-free humidification, intelligent controls, and a user-friendly design, the 3Lite delivers 14 hours of quiet, efficient operation with a 4L water tank. With the smart app and voice control, easy maintenance, and no filter replacements needed, the 3Lite offers simple, cost-effective humidification for modern homes.
Prioritizing Health for a Comfortable Environment
The Smartmi Evaporative Humidifier 3lite is designed with health and well-being at its core. Mist-free humidification is ideal for sensitive individuals, and this technology ensures optimal humidity levels without the side effects of mist, creating a healthier, allergen-free environment. It allows a peaceful night's sleep with near-silent performance, ensuring restful, uninterrupted slumber. With a 4L large water tank & a 280mL/h humidification output, the 3Lite provides up to 14 hours of continuous operation, and it is perfect for maintaining optimal humidity levels throughout the day and night.
Intelligent Features for Modern Living
The Smartmi Evaporative Humidifier 3Lite is equipped with cutting-edge technology to bring ease and convenience to everyday life. The intelligent constant humidity mode automatically adjusts the humidity from 30% to 60%, ensuring consistent comfort in any environment. Users can manage their humidifier remotely with the Mi Home app or enjoy hands-free control via smart voice assistants, like Google Assistance, Amazon Alexa, and Yandex Alice, making it easier than ever to stay comfortable.
User-Friendly Design for Maximum Convenience
Designed with the user in mind, the Smartmi 3Lite simplifies maintenance and operation. Say goodbye to costly filter replacements – simply add water and use, saving both money and time. The top-fill design allows for hassle-free refilling, while the modular design, removable evaporation disc, and water tank make cleaning a breeze. The intuitive touch interface ensures simple operation, and the water level sidebar lets you monitor water levels in real-time. With an automatic shutdown when the water runs low and when the tank is removed, Smartmi ensures safe and reliable operation.
Pricing and Availability
The Smartmi Evaporative Humidifier 3lite is the perfect companion for anyone looking to enhance their living environment with improved health and comfort. Set to launch in the CIS, Europe, and Asia Pacific in Q4 2024, it will be offered at an affordable price. This humidifier delivers smart, simple, and efficient humidity control for your home. For more information, visit www.smartmiglobal.com or follow us on social media for the latest updates.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Smartmi Launches the New Evaporative Humidifier 3lite
ALL-RISE Study Included Over 1,924 Patients in 59 Sites Across
North America, Asia, Europe and the Middle East
NEWPORT BEACH, Calif., Jan. 3, 2025 /PRNewswire/ -- CathWorks, a global leader in medical device digital health innovations, announced today the successful completion of enrollment of the Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment (ALL-RISE) randomized controlled trial (RCT). This landmark study represents a significant milestone in the field of interventional cardiology, evaluating the clinical and economic benefits of the CathWorks FFRangio® System in diagnosing and treating coronary artery disease (CAD), offering potentially groundbreaking evidence that could redefine the standard of care.
The ALL-RISE Study included over 1,924 patients across 59 sites in North America, Asia, Europe and the Middle East. Participants presenting with coronary stenoses of intermediate significance and requiring physiology assessment were randomized to receive either FFRangio-guided treatment or invasive pressure wire-guided treatment. Notably, this was the first-ever randomized controlled trial in the United States to assess clinical outcomes using an angiography-based tool for physiologic lesion assessment.
In a joint statement, the ALL-RISE Study Chair, Dr. Ajay J. Kirtane (NewYork-Presbyterian/Columbia University Irving Medical Center) and Principal Investigators, Dr. William Fearon (Stanford University) and Dr. Allen Jeremias (St. Francis Hospital & Heart Center), stated, "On behalf of the study executive committee, we would like to congratulate and thank all the global investigators, study coordinators and patients who collectively enabled this incredible accomplishment. The high level of engagement and record speed of enrollment parallel the growing adoption of FFRangio globally. We look forward to sharing the results of this landmark study after clinical follow-up is completed."
CathWorks Sr. Director of Clinical Affairs, Alex Froimovich M.D., added, "The completion of ALL-RISE enrollment marks a significant milestone for our company and team's mission to transform how cardiovascular disease is diagnosed and treated. We believe this study, adding to FFRangio's growing body of clinical evidence, has the potential to significantly advance the field of coronary physiology and close the gap between its current adoption and the appropriate use guidelines recommendations. FFRangio has already demonstrated higher diagnostic accuracy over all other angio-based technologies, highlighting the fact that not all angio-based technologies are created equal, and therefore technology-specific clinical data are needed."
Cardiovascular disease (CVD) remains the leading cause of death in the United States. According to the American Heart Association's (AHA) 2024 Heart Disease and Stroke Statistics Update, CVD accounted for 931,578 deaths in the U.S. in 2021, and close to 18 million deaths globally. Coronary artery disease (CAD) is the single largest contributor, responsible for over 40% of CV deaths. CathWorks believes the results from the ALL-RISE study will build on what the company refers to as a new era in physiology, underscoring FFRangio as the new standard of care with the potential to drive better patient outcomes while delivering tangible economic and resource utilization benefits to healthcare systems.
ABOUT CATHWORKS
CathWorks is the leader in digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated. The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick and reliable intraprocedural FFRangio values for the entire coronary tree. For more information on CathWorks, visit www.cath.works and follow @CathWorks on LinkedIn.
Investors:
Mike Feher
mike.feher@cath.works
Media:
Sarita Monico
sarita.monico@cath.works
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial
